June 24, 2010
Company News: Pfizer
Pfizer said last night that it suspended the osteoarthritis clinical program for investigational compound tanezumab following a certain number of reports that tanezumab patients had their osteoarthritis worsen leading to joint replacement. The product was being studied as a way to treat pain associated with the condition. Pfizer said the adverse event has not been observed in non-osteoarthritis patient populations taking tanezumab. Pfizer said the monoclonal antibody is still being studied in conditions such as cancer pain, low back pain and pain associated with diabetes.